Acute Respiratory Distress Syndrome |
INTRODUCTION Background:
Since World War I, it has been known that patients with nonthoracic
injuries, massive transfusion, sepsis, and other conditions may develop
respiratory distress, diffuse lung infiltrates, and respiratory failure,
sometimes after a delay of hours to days. After Ashbaugh described 12 such
patients in 1967, the term adult respiratory distress syndrome (ARDS) was used
to describe this condition. However, clear definition of the syndrome was needed
to allow research into its pathogenesis and treatment. This was most recently
refined in 1994 by the American-European Consensus Conference (AECC) on ARDS.
The term acute respiratory distress syndrome rather than adult respiratory
distress syndrome was used because the syndrome occurs in both adults and
children.
ARDS was recognized as the most severe form of a diffuse alveolar injury,
acute lung injury (ALI). Based on the AECC, ARDS is defined as an acute
condition characterized by bilateral pulmonary infiltrates and severe hypoxemia
in the absence of evidence for cardiogenic pulmonary edema. By these criteria,
the severity of hypoxemia needed to make the diagnosis of ARDS is defined by the
ratio of the patient's arterial oxygen partial pressure (PaO2) to the
fractional concentration of oxygen in the inspired air (FIO2) ratio
(PaO2 /FIO2). In ARDS, this ratio is less than 200.
Cardiogenic pulmonary edema is excluded by a pulmonary capillary wedge pressure
of less than 18 mm Hg in patients with a Swan-Ganz catheter in place or by
clinical criteria consistent with a normal left atrial pressure. The AECC used
the term ALI to define less severe respiratory impairment, as defined by a
PaO2 /FIO2 ratio of 300 or less.
Pathophysiology: ARDS is associated with diffuse damage to
the alveoli and lung capillary endothelium. The early phase is described as
being exudative, whereas the later phase is fibroproliferative in character.
Early ARDS is characterized by an increase in the permeability of the
alveolar-capillary barrier leading to an influx of fluid into the alveoli. The
alveolar-capillary barrier is formed by the microvascular endothelium and the
epithelial lining of the alveoli. Hence, a variety of insults resulting in
damage either to the vascular endothelium or the alveolar epithelium could
result in ARDS. The main site of injury may be focused on either the vascular
endothelium (eg, sepsis) or the alveolar epithelium (eg, aspiration of gastric
contents).
Injury to the endothelium results in increased capillary permeability and the
influx of protein-rich fluid into the alveolar space. Injury to the alveolar
lining cells also promotes pulmonary edema formation. There are 2 types of
alveolar epithelial cells, type I, comprising 90% of the alveolar epithelium are
injured easily. Damage to type I cells allows both increased entry of fluid into
the alveoli and decreased clearance of fluid from the alveolar space. Type II
cells are relatively more resistant to injury. However, type II cells have
several important functions, including the production of surfactant, ion
transport, and proliferation and differentiation into type l cells after
cellular injury. Damage to type II cells results in decreased production of
surfactant with resultant decreased compliance and alveolar collapse.
Interference with the normal repair processes in the lung may lead to the
development of fibrosis.
Neutrophils are thought to play an important role in the pathogenesis of
ARDS. Evidence for this comes from studies of bronchoalveolar lavage (BAL) and
lung biopsy specimens in early ARDS. Despite the apparent importance of
neutrophils in ARDS, the syndrome may develop in profoundly neutropenic
patients, and infusion of granulocyte colony-stimulating factor (GCSF) in
patients with ventilator-associated pneumonia does not promote the development
of ARDS. This and other evidence suggest to some that the neutrophils observed
in ARDS may be reactive rather than having a causal role.
Cytokines, such as tumor necrosis factor (TNF), leukotrienes, macrophage
inhibitory factor, and numerous others, along with platelet sequestration and
activation, also are important in the development of ARDS. An imbalance of
pro-inflammatory and anti-inflammatory cytokines is thought to occur after an
inciting event, such as sepsis. Evidence from animal studies suggests that the
development of ARDS may be promoted by the positive airway pressure delivered to
the lung by mechanical ventilation. This is termed ventilator-associated lung
injury.
ARDS is an inhomogeneous process. Relatively normal alveoli, more compliant
than affected alveoli, may become overdistended by the delivered tidal volume
resulting in barotrauma (pneumothorax and interstitial air). Alveoli already
damaged by ARDS may suffer further injury by the shear forces exerted by the
cycle of collapse at end expiration and reexpansion by positive pressure at the
next inspiration; so called volutrauma. In addition to the mechanical effects on
alveoli, these forces promote the secretion of pro-inflammatory cytokines with
resultant worsening inflammation and pulmonary edema. The use of positive
end-expiratory pressure (PEEP) to diminish alveolar collapse and the use of low
tidal volumes and limited levels of inspiratory filling pressures appear to be
beneficial in diminishing the observed ventilator-associated lung injury.
ARDS is associated with severe hypoxemia, and high inspired oxygen
concentrations, therefore, are required to maintain adequate tissue oxygenation
and life. Unfortunately, oxygen toxicity may promote further lung injury.
Generally, oxygen concentrations greater than 65% for prolonged periods (days)
result in diffuse alveolar damage, hyaline membrane formation, and, eventually,
fibrosis.
ARDS is uniformly associated with pulmonary hypertension. Pulmonary artery
vasoconstriction likely contributes to ventilation-perfusion mismatch and is one
of the mechanisms of hypoxemia in ARDS. Normalization of pulmonary artery
pressures occurs as the syndrome resolves. The development of progressive
pulmonary hypertension is associated with a poor prognosis.
The acute phase of ARDS usually resolves completely. Less commonly, there is
residual pulmonary fibrosis, in which the alveolar spaces are filled with
mesenchymal cells and new blood vessels. This process seems to be facilitated by
interleukin (IL)-1. Progression to fibrosis may be predicted early in the course
by the finding of increased levels of procollagen peptide III (PCP-III) in the
fluid obtained by BAL. This and the finding of fibrosis on biopsy correlate with
an increased mortality rate.
Frequency: Mortality/Morbidity: Until the 1990s, most studies reported
a mortality rate for ARDS of 40-70%. However, 2 reports in the 1990s, one from a
large county hospital in Seattle and one from the UK, suggested much lower
mortality rates, in the 30-40% range. Possible explanations for the improved
survival rates may be better understanding and treatment of sepsis, recent
changes in the application of mechanical ventilation, and better overall
supportive care of the critically ill patients.
Sex: For ARDS associated with sepsis and most other causes,
there appears to be no differences in the incidence between males and females.
However, in trauma patients only, there may be a slight preponderance of the
disease in females.
Age: ARDS may occur at any age. The age distribution
reflects the predilection of the underlying causes.
CLINICAL
History:
Physical:
Causes:
DIFFERENTIALS
Pulmonary hemorrhage
WORKUP
Lab Studies: Imaging Studies: Other Tests: Procedures: Staging: In the 1980s, Murray and coworkers developed a lung
injury scoring system. This system was based on 4 parameters, as follows:
severity of consolidation based upon CXR, severity of hypoxemia based upon the
PaO2/FIO2 ratio, lung compliance, and level of PEEP
required. This scoring system has proven helpful in clinical research in ARDS.
TREATMENT
Medical Care:
There is no specific therapy for ARDS. Treatment of the underlying
condition is essential, along with supportive care and appropriate ventilator
and fluid management. As infection is often the underlying cause of ARDS,
careful assessment of the patient for infected sites and institution of
appropriate antibiotic therapy are key. In some instances, drainage of infected
fluid collections or surgical debridement or resection of an infected site, such
as ischemic bowel, may be essential because sepsis-associated ARDS does not
resolve without such management. With the development of the NIH-sponsored ARDS
Study Network, large well-controlled trials of ARDS therapies are underway. Thus
far, the only treatment found to improve survival rates in such a study is a
mechanical ventilation strategy employing low tidal volumes.
Contraindications to NIPPV include a diminished level of consciousness or
other causes of decreased airway protection reflexes, inadequate cough,
vomiting or upper gastrointestinal bleeding, inability to properly fit mask,
poor patient cooperation, and hemodynamic instability. There is now evidence that a protective ventilation strategy employing low
tidal volumes improves survival rates compared to conventional tidal volumes.
In a study conducted by the ARDS Network, patients with ALI and ARDS were
randomized to mechanical ventilation at a tidal volume of 12 cc per kg of
predicted body weight and an inspiratory pressure of 50 cm or less versus a
tidal volume of 6 cc/kg and an inspiratory pressure of 30 cm or less. The
study was stopped early after interim analysis of 861 patients demonstrated
that subjects in the low tidal volume group had a significantly lower
mortality rate (31% vs 39.8%).
While previous studies employing low tidal volumes allowed patients to be
hypercapnic (permissive hypercapnia) and acidotic to achieve the protective
ventilation goals of low tidal volume and low inspiratory airway pressure, the
ARDS Network Study allowed increases in respiratory rate and administration of
bicarbonate to correct acidosis. This may account for the positive outcome in
this study compared to earlier studies that had failed to demonstrate a
benefit. Thus, mechanical ventilation with a tidal volume of 6 cc per kg
predicted body weight is recommended, with adjustment of the tidal volume to
as low as 4 cc/kg if needed to limit the inspiratory plateau pressure to 30 cm
of water or less.
The ventilator rate should be increased and bicarbonate administered as
needed to maintain the pH at a near normal level. In the ARDS Network Study,
patients ventilated with lower tidal volumes required higher levels of PEEP
(9.4 vs 8.6 cm) to maintain oxygen saturation at 85% or more. Some authors
have speculated that the higher levels of PEEP also may have contributed to
the improved survival rates. In general, patients tolerate CPAP well, and CPAP usually is used rather
than PEEP. It is thought that the use of appropriate levels of CPAP improves
outcome in ARDS and, by maintaining alveoli in an expanded state throughout
the respiratory cycle, may decrease shear forces that promote ventilator
associated lung injury.
The best method for finding the optimal level of CPAP in patients with
ARDS is controversial. Some favor the use of just enough CPAP to allow
reduction of the FIO2 below 65%. Another approach, favored by
Amato and associates, is the so-called open lung approach, in which the
appropriate level is determined by the construction of a static pressure
volume curve. This is an S-shaped curve, and the optimal level of PEEP is
just above the lower inflection point. Using this approach, the average PEEP
level required is 15 cm. Surgical Care: The treatment of ARDS is medical. Surgical
intervention may be required for some of the underlying causes of ARDS, as
previously noted. In patients requiring prolonged mechanical ventilation,
tracheostomy eventually is required.
Extracorporeal membrane oxygenation (ECMO) was shown in a large multicenter
trial in the 1970's not to improve mortality in ARDS. Still, it remains a
potential heroic measure in select cases.
Consultations: Treatment of patients with ARDS requires
special expertise with mechanical ventilation and management of critical
illness. Thus, a physician specializing in pulmonary medicine or critical care
should be consulted.
Diet: Institution of nutritional support after 48-72 hours
of mechanical ventilation usually is recommended. Unless contraindicated because
of an acute abdomen, ileus, gastrointestinal bleeding, or other conditions,
enteral nutrition via a feeding tube is preferable to intravenous
hyperalimentation. A low carbohydrate, high fat enteral formula containing
components that are anti-inflammatory and vasodilating (eicosapentaenoic acid
and linoleic acid) with antioxidants has been shown to improve outcome in ARDS.
Activity: Patients with ARDS are at bedrest. Frequent
position change and passive and, if possible, active range of motion activities
of all muscle groups should be started immediately.
MEDICATION
No drug has proved
beneficial in the prevention or management of ARDS. The early administration of
corticosteroids in septic patients does not prevent the development of ARDS.
Numerous pharmacologic therapies, including the use of inhaled synthetic
surfactant, intravenous antibody to endotoxin, ketoconazole, and ibuprofen have
been tried and are not effective. Small sepsis trials suggest a potential role
for antibody to TNF and recombinant IL-1 receptor antagonist. Inhaled nitric
oxide (NO), a potent pulmonary vasodilator looked promising in early trials, but
in larger controlled trials did not change mortality rates in adults with ARDS.
A potential role exists for corticosteroids in patients with late ARDS
(fibroproliferative phase) because they decrease inflammation by suppressing
migration of polymorphonuclear leukocytes and reversing increased capillary
permeability. This may be considered rescue therapy in selected patients, but
widespread use is not recommended pending the results of an ARDS
Network Drug Category: Corticosteroids -- Development of
the late phase of ARDS may represent continued, uncontrolled inflammation
requiring treatment with IV corticosteroids.
Chemical Worker's Lung
Farmer's Lung
Hanta Virus
Pulmonary Syndrome
Influenza
Legionellosis
Nosocomial Pneumonia
Opioid Abuse
Perioperative
Pulmonary Management
Pneumococcal Infections
Pneumocystis
Carinii Pneumonia
Pneumonia, Bacterial
Pneumonia, Viral
Pulmonary Edema,
Cardiogenic
Pulmonary Edema, Neurogenic
Pulmonary
Eosinophilia
Respiratory Failure
Sepsis, Bacterial
Septic Shock
Systemic Inflammatory Response
Syndrome
Toxic
Shock Syndrome
Toxicity, Cocaine
Toxicity, Salicylate
Transfusion
Reactions
Tumor
Lysis Syndrome
Other Problems to be Considered:
Near drowning
Drug reaction
Noncardiogenic
pulmonary edema
Hamman-Rich syndrome
Retinoic acid syndrome
Acute
hypersensitivity pneumonitis
Transfusion-related acute lung injury
(TRALI)
Acute eosinophilic pneumonia
Reperfusion injury
Leukemic
infiltration
Pulmonary alveolar proteinosis
Fat embolism syndrome
Histologic Findings:
The
histologic changes in ARDS are those of diffuse alveolar damage. An exudative
phase occurs in the first several days and is characterized by interstitial
edema, alveolar hemorrhage and edema, alveolar collapse, pulmonary capillary
congestion, and hyaline membrane formation. These histologic changes are
nonspecific and do not provide information that would allow the pathologist to
determine the cause of the ARDS. A biopsy performed after several days begins to
show organization of the intra-alveolar exudate and repair, the proliferative
phase of ARDS, which is characterized by the growth of type 2 pneumocytes in the
alveolar walls and the appearance fibroblasts, myofibroblasts, and collagen
deposition in the interstitium. The final phase of ARDS is fibrotic. Alveolar
walls are thickened by connective tissue rather than edema or cellular
infiltrate.
comparing VCV to PCV in patients with ARDS, Esteban found that
PCV resulted in fewer organ system failures and lower mortality rates than
VCV, despite use of the same tidal volumes and peak inspiratory pressures. A
larger trial is needed before a definite recommendation is made.
and survival at 6 months was
unchanged compared with care in the supine position, despite a significant
improvement in oxygenation. Further study may still be required as the
patients in this study were kept in the prone position for only 7 hours per
day.
trial now underway.
Drug Name |
Methylprednisolone (Solu-Medrol) -- High-dose methylprednisolone has been used in several small trials of patients with ARDS who have persistent pulmonary infiltrates, fever, and high oxygen requirement despite resolution of pulmonary or extrapulmonary infection. Pulmonary infection is assessed with bronchoscopy and bilateral BAL and quantitative culture. |
---|---|
Adult Dose | 2-3 mg/kg/d IV in divided doses |
Pediatric Dose | Not established |
Contraindications | Documented hypersensitivity; active tuberculosis; uncontrolled bacterial, viral, fungal, or tubercular infection |
Interactions | Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels of methylprednisolone; phenobarbital, phenytoin, and rifampin may decrease levels of methylprednisolone (adjust dose); monitor patients for hypokalemia when taking medication concurrently with diuretics |
Pregnancy | C - Safety for use during pregnancy has not been established. |
Precautions | Hyperglycemia, may mask fever and signs of acute abdomen |
FOLLOW-UP
Further Inpatient Care:
Transfer:
Deterrence/Prevention:
Complications:
Prognosis:
MISCELLANEOUS
Medical/Legal Pitfalls:
Home page, Drug information's ,Regional anesthesia ,Index for diseases ,Index for diseases, Perioperative medicine, Search engine, Accreditation, Learn Arabic Warfare, Anesthesia LINKS, Orthopedic LINKS, Midline
Constructed by Dr N.A. Nematallah Consultant in perioperative medicine and intensive therapy, Al Razi Orthopedic Hospital , State of Kuwait, email : razianesth@freeservers.com